Patent pooling for promoting access to antiretroviral drugs (ARVs) - A strategic option for India

Open AIDS Journal

Volumn 4, Issue , 2010, Pages 41-53

  Satyanarayana, Kanikaram ^a   Srivastava, Sadhana ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DEVELOPING COUNTRY; DRUG COST; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN RIGHTS; INDIA; PATENT; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; STRATEGIC PLANNING; VIRUS LOAD;

EID: 77953364504     PISSN: None     EISSN: 18746136     Source Type: Journal    
DOI: 10.2174/1874613601004020041     Document Type: Article

References (38)

1. HIV sentinel surveillance and HIV estimations 2007 a technical brief & HIV Burden In India. Available from: www.nacoonline.org/upload/Publication/M&E%20Surveillance,%20Research/HIV%20Sentinel%20Surveillance%20and%20HIV%20Estimation%202007_A%20Technical%20Brief.pdf (accessed July 2009).
2. Available from: http://www.nacoonline.org/upload/Documents/List%20of%20127%20ART%20centres%20with%20addresses.pdf (accessed July 2009).
3. Antiretroviral Therapy Guidelines for HIV-Infected Adults and Adolescents Including Post-exposure Prophylaxis. (New Delhi, India National AIDS Control Organization), 2007. Available from: www.nacoonline.org/upload/documents/Antiretroviral%20therapy%20guidelines%20for%20%HIVinfected%20adults%20adolescents%20including%20including%20post-exposure.pdf. (accessed July 2009).
4. Available from: http://infochangeindia.org/200811287509/Health/News/HIV-prevalence-down-in-high-risk-states-but-up-in-low-risk-ones.html. (accessed July 2009).
5. Highly Active Antiretroviral Therapy-HAART. Available from: http://www.sfaf.org/beta/2009_win/haartchar (accessed August 2009).
6. Overview of HIV and AIDS in India. Available from: www.avert.org. (Last updated March 09, 2009).
7. Electronic Orange Book. Available from: http://www.fda.gov/cder/ob/default.htm (Last updated 2009).
8. Available from: www.fda.gov/bbs/topics/news/2007/new01677.html. (accessed August 2009).
9. Available from: www.fda.gov/bbs/topics/NEWS/2007/NEW01726.html (accessed July 2009).
10. USFDA: HIV prevalence data\President's Emergency Plan for AIDS Relief. Available from: www.fda.gov/oia/pepfar.html (Last updated May 14, 2009).
11. Prioritizing Second-Line Antiretroviral Drugs for Adults and Adolescents: a Public Health Approach (First & Second Line). Available from: www.who.int/hiv/pub/meetingreports/second_line_art_report_2008.pdf. (accessed July 2009).
12. Available from: www.nacoonline.org/upload/Divisions/CST/ART% 20Rollout-%20Dec%2008.xls. (accessed August 2009).
13. Available from: www.nacoonline.org/National_AIDS_Control_Program/PEP_full/ (accessed August 2009).
14. HIV prevelance data\USFDA Approved HIV AIDS Drug. Available from: http://www.fda.gov/oashi/aids/virals.html (updated January, 2008).
15. WHO, UNAIDS, UNICEF. Towards Universal Access - Scaling up priority HIV/AIDS interventions in the health sector - Progress Report (Geneva, World Health Organization), 2008. Available from: http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf (accessed July 2009).
16. Medicine Sans Frontiers (MSF). Running in Place: Too Many Patients Still in Urgent Need of HIV/AIDS Treatment. Medecins Sans Frontieres (MSF) Briefing Document on HIV/AIDS. XVII International AIDS Conference 3-8 August 2008, Mexico City.
17. Boulle A, Orrell C, Kaplan R, et al. Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007; 12: 753-60.
18. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. (Geneva, World Health Organization), 2006 revision.
19. Agreement on Trade-Related Aspects of Intellectual Property Rights Annex 1C, Art. 70 §8 (entered into force 1994). Available from: http://www.wto.org/english/tratop_e/trips_e/t_agm2_e.htm. (accessed August 2009).
20. Dionisio D, Messeri D. Impending flop for brand antiretrovirals in the emerging markets? Open AIDS J 2008; 2: 68-71.
21. Satyanarayana K. TRIPS, patents & HIV/AIDS drugs. Indian J Med Res 2005; 121: 211-14. Available from: http://www.icmr.nic.in/ijmr/2005/april/editorial2.pdf (accessed July 2009).
22. Diane V, Havlir VD, Hammer SM. Patents versus patients? antiretroviral therapy in India. N Engl J Med 2005; 353: 749-51.
23. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Secondline antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 2008; 22: 1305-12.
24. Gilead Licenses Viread to Eight Generic Companies. Available from: http://www.redorbit.com/news/health/670013/gilead_licenses_viread_to_eight_generic_ companies/index.html (accessed July 2009).
25. Kivela J, O'Brien D, Mills C, Sabapathy K. The price of change - replacing stavudine with tenofovir in first-line ART in scaling-up settings. XVII International AIDS Conference 3-8 August 2008, Mexico City. Available from: http://www.doctorswithoutborders.org/events/symposiums/2008-aids-iac/assets/files/MSF-Mexico-IAC-Briefing-Document.pdf (accessed July 2009)
26. NGO Files Pre-Grant Opposition against Anti-HIV Drug, Combivir. Available from: http://www.bio-medicine.org/medicine-news/NGO-Files-Pre-Grant-Opposition-Against-Anti-HIV-Drug-Combivir-8908-1/ (accessed August 2009).
27. GSK Withdraws Combivir Patent Application from India and Thailand. Available from: http://www.twnside.org.sg/title2/intellectual_property/info.service/twn%20ipr%20info%20090603/090603.doc (accessed August 2009).
28. Abbott Labs' bid for anti-HIV drug patent to face stiff challenge. Available from: http://www.livemint.com/2007/08/27001549/Abbott-Labs8217-bid-for-ant.html?d=1 (accessed July 2009).
29. Doha WTO Ministerial 2001: Ministrial Declaration. Available from: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecle.htm (accessed July 2009).
30. Satyanarayana K, Srivastava S. Poverty, health & intellectual property rights with special reference to India. Indian J Med Res 2007; 126: 390-406. Available from: http://www.icmr.nic.in/ijmr/2007/october/1016.pdf
31. Satyanarayana K. Towards equitable health care: drug prices, and beyond. Indian J Med Res 2008; 127: 301-4.
32. Why are AIDS drugs unaffordable in India? Available from: http://infochangeindia.org/200801086828/Agenda/HIV/AIDS-Big-Questions/Why-are-AIDS-drugs-unaffordable-in-India.html (accessed August 2009).
33. UNITAID moves towards a patent pool for medicines [press release]. UNITAID, Geneva, 9 July 2008. Available from: http://www.unitaid.eu/en/20080709113/News/UNITAID-moves-towards-a-patent-pool-for-medicines.html (accessed July 2009).
34. t' Hoen E. How a 'Patent Pool' Could Help Solve the Access to Medicines Crisis. Available from: http://www.msfaccess.org/media-room/press-releases/msf-welcomes-unitaid-patent-pool-endorsement/ (accessed August 2009).
35. Global Strategy and plan of action on public health, innovation and intellectual property. 61st World Health Assembly WHA 61.21 24 May 2008. Available from: http://www.who.int/gb/ebwha/pdf_files/A61/A61_R21-en.pdf (accessed July 2009).
36. Satyanarayana K. The Inter-Governmental Working Group on Public Health, Innovation and Intellectual Property (IGWG) - The way ahead. Indian J Med Res 2008:128: 577-80. Available from: http://www.icmr.nic.in/ijmr/2008/november/editorial4.pdf (accessed August 2009).
37. Sukkar E. Patent pools: an idea whose time has come. BMJ 2009; 338: b1630.
38. Untangling the Web of ARV Price Reductions, 11th edition. MSF, July 2008. Available from: http://www.msfaccess.org/main/hiv-aids/untangling-the-web-of-antiretroviral-price-reductions-11th-edition/ (accessed July 2009).